APA

Socié G., Milpied N., Yakoub-Agha I., Bay J., Fürst S., Bilger K., Suarez F., Michallet M., Lewalle P., Liens D., Mathis C., Guemas E. & Vernant J. (20200109). Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. : Blood advances.

Chicago

Socié Gérard, Milpied Noel, Yakoub-Agha Ibrahim, Bay Jacques-Olivier, Fürst Sabine, Bilger Karin, Suarez Felipe, Michallet Mauricette, Lewalle Philippe, Liens David, Mathis Catherine, Guemas Eric and Vernant Jean-Paul. 20200109. Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. : Blood advances.

Harvard

Socié G., Milpied N., Yakoub-Agha I., Bay J., Fürst S., Bilger K., Suarez F., Michallet M., Lewalle P., Liens D., Mathis C., Guemas E. and Vernant J. (20200109). Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. : Blood advances.

MLA

Socié Gérard, Milpied Noel, Yakoub-Agha Ibrahim, Bay Jacques-Olivier, Fürst Sabine, Bilger Karin, Suarez Felipe, Michallet Mauricette, Lewalle Philippe, Liens David, Mathis Catherine, Guemas Eric and Vernant Jean-Paul. Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. : Blood advances. 20200109.